ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HRTX vs RNTX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Heron Therapeutics Inc. (NASDAQ) VS. Rein Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: HRTX 1 — RNTX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRTX VS. RNTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HRTX RNTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 73.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -1.60% — — TIE /operating-margins <GO>
Net Profit Margin -12.90% — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.7 44.4 -0.70 RNTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $56.0M $54.8M $1.2M HRTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HRTX REV RNTX REV HRTX GROSS % RNTX GROSS % HRTX FCF RNTX FCF
FY 2025 $154.9M $141.8M 73.3% — -$27.9M -$19.4M
FY 2024 $144.3M $182.3M 73.2% — -$24.2M -$22.3M
FY 2023 $309.7M $45.6M — — -$58.8M -$19.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRTX // BETA —
RNTX // BETA —